Evidence map›Paper›PMID 25085362›Full record

ArticleNeuro-oncology2015

Adult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling.

Nicolas Goffart, Jérôme Kroonen, Emmanuel Di Valentin, Matthias Dedobbeleer, Alexandre Denne, Philippe Martinive, Bernard Rogister

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Radiosynthesis and preclinical evaluation of aEJNMMI radiopharmacy and chemistry · 2024
    Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Nicolas GoffartLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.D., M.D., B.R.); Human Genetics, CHU and University of Liège, Liège, Belgium (J.K.); The T&P Bohnenn Laboratory for Neuro-Oncology, Department of Neurosurgery, University Medical Center Utrecht, Utrecht, The Netherlands (J.K.); GIGA-Viral Vector Platform, University of Liège, Liège, Belgium (E.D.V.); Unit of Radiology and Radiotherapy, CHU and University of Liège, Liège, Belgium (P.M.); Department of Neurology, CHU and University of Liège, Liège, Belgium (B.R.); GIGA-Development, Stem Cells and Regenerative Medicine, University of Liège, Liège, Belgium (B.R.).
Jérôme KroonenLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.D., M.D., B.R.); Human Genetics, CHU and University of Liège, Liège, Belgium (J.K.); The T&P Bohnenn Laboratory for Neuro-Oncology, Department of Neurosurgery, University Medical Center Utrecht, Utrecht, The Netherlands (J.K.); GIGA-Viral Vector Platform, University of Liège, Liège, Belgium (E.D.V.); Unit of Radiology and Radiotherapy, CHU and University of Liège, Liège, Belgium (P.M.); Department of Neurology, CHU and University of Liège, Liège, Belgium (B.R.); GIGA-Development, Stem Cells and Regenerative Medicine, University of Liège, Liège, Belgium (B.R.).
Emmanuel Di ValentinLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.D., M.D., B.R.); Human Genetics, CHU and University of Liège, Liège, Belgium (J.K.); The T&P Bohnenn Laboratory for Neuro-Oncology, Department of Neurosurgery, University Medical Center Utrecht, Utrecht, The Netherlands (J.K.); GIGA-Viral Vector Platform, University of Liège, Liège, Belgium (E.D.V.); Unit of Radiology and Radiotherapy, CHU and University of Liège, Liège, Belgium (P.M.); Department of Neurology, CHU and University of Liège, Liège, Belgium (B.R.); GIGA-Development, Stem Cells and Regenerative Medicine, University of Liège, Liège, Belgium (B.R.).
Matthias DedobbeleerLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.D., M.D., B.R.); Human Genetics, CHU and University of Liège, Liège, Belgium (J.K.); The T&P Bohnenn Laboratory for Neuro-Oncology, Department of Neurosurgery, University Medical Center Utrecht, Utrecht, The Netherlands (J.K.); GIGA-Viral Vector Platform, University of Liège, Liège, Belgium (E.D.V.); Unit of Radiology and Radiotherapy, CHU and University of Liège, Liège, Belgium (P.M.); Department of Neurology, CHU and University of Liège, Liège, Belgium (B.R.); GIGA-Development, Stem Cells and Regenerative Medicine, University of Liège, Liège, Belgium (B.R.).
Alexandre DenneLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.D., M.D., B.R.); Human Genetics, CHU and University of Liège, Liège, Belgium (J.K.); The T&P Bohnenn Laboratory for Neuro-Oncology, Department of Neurosurgery, University Medical Center Utrecht, Utrecht, The Netherlands (J.K.); GIGA-Viral Vector Platform, University of Liège, Liège, Belgium (E.D.V.); Unit of Radiology and Radiotherapy, CHU and University of Liège, Liège, Belgium (P.M.); Department of Neurology, CHU and University of Liège, Liège, Belgium (B.R.); GIGA-Development, Stem Cells and Regenerative Medicine, University of Liège, Liège, Belgium (B.R.).
Philippe MartiniveLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.D., M.D., B.R.); Human Genetics, CHU and University of Liège, Liège, Belgium (J.K.); The T&P Bohnenn Laboratory for Neuro-Oncology, Department of Neurosurgery, University Medical Center Utrecht, Utrecht, The Netherlands (J.K.); GIGA-Viral Vector Platform, University of Liège, Liège, Belgium (E.D.V.); Unit of Radiology and Radiotherapy, CHU and University of Liège, Liège, Belgium (P.M.); Department of Neurology, CHU and University of Liège, Liège, Belgium (B.R.); GIGA-Development, Stem Cells and Regenerative Medicine, University of Liège, Liège, Belgium (B.R.).
Bernard RogisterLaboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Liège, Belgium (N.G., A.D., M.D., B.R.); Human Genetics, CHU and University of Liège, Liège, Belgium (J.K.); The T&P Bohnenn Laboratory for Neuro-Oncology, Department of Neurosurgery, University Medical Center Utrecht, Utrecht, The Netherlands (J.K.); GIGA-Viral Vector Platform, University of Liège, Liège, Belgium (E.D.V.); Unit of Radiology and Radiotherapy, CHU and University of Liège, Liège, Belgium (P.M.); Department of Neurology, CHU and University of Liège, Liège, Belgium (B.R.); GIGA-Development, Stem Cells and Regenerative Medicine, University of Liège, Liège, Belgium (B.R.).
University Medical Center Utrecht · NLUniversity of Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with glioblastoma multiforme (GBM) have an overall median survival of 15 months. This catastrophic survival rate is the consequence of systematic relapses that could arise from remaining glioblastoma stem cells (GSCs) left behind after surgery. We previously demonstrated that GSCs are able to escape the tumor mass and specifically colonize the adult subventricular zones (SVZs) after transplantation. This specific localization, away from the initial injection site, therefore represents a high-quality model of a clinical obstacle to therapy and relapses because GSCs notably retain the ability to form secondary tumors.

methodIn this work, we questioned the role of the CXCL12/CXCR4 signaling in the GSC-specific invasion of the SVZs.

resultsWe demonstrated that both receptor and ligand are respectively expressed by different GBM cell populations and by the SVZ itself. In vitro migration bio-assays highlighted that human U87MG GSCs isolated from the SVZs (U87MG-SVZ) display stronger migratory abilities in response to recombinant CXCL12 and/or SVZ-conditioned medium (SVZ-CM) compared with cancer cells isolated from the tumor mass (U87MG-TM). Moreover, in vitro inhibition of the CXCR4 signaling significantly decreased the U87MG-SVZ cell migration in response to the SVZ-CM. Very interestingly, treating U87MG-xenografted mice with daily doses of AMD3100, a specific CXCR4 antagonist, prevented the specific invasion of the SVZ. Another in vivo experiment, using CXCR4-invalidated GBM cells, displayed similar results.

conclusionTaken together, these data demonstrate the significant role of the CXCL12/CXCR4 signaling in this original model of brain cancer invasion.

Indexed as

AnimalsBenzylaminesBrain NeoplasmsCell Line, TumorChemokine CXCL12CyclamsDisease Models, AnimalFemaleGlioblastomaHeterocyclic CompoundsHumansLateral VentriclesMiceMice, NudeNeoplasm InvasivenessNeoplastic Stem CellsBenzylaminesChemokine CXCL12CXCL12 protein, humanCXCR4 protein, humanCyclamsHeterocyclic CompoundsplerixaforReceptors, CXCR4cancer stem cellsCXCL12invasionstem cell microenvironment

Identifiers

PMID25085362
PMCPMC4483049
OpenAlexW2105284981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.